Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs

International Journal of Molecular Medicine

Volumn 29, Issue 1, 2012, Pages 102-106

  Mujtaba, Taskeen ^a   Kanwar, Jyoti ^a   Wan, Sheng Biao ^b   Chan, Tak Hang ^b,c   Dou, Q Ping ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Bortezomib; Curcumin; Curcumin analogs; Drug resistance; Multiple myeloma

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CURCUMIN; PROTEASOME INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIZATION; DRUG SOLUBILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; SOLID TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; DRUG SYNERGISM; HUMANS; IMMUNOBLOTTING; MULTIPLE MYELOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PYRAZINES;

EID: 84855162753     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.814     Document Type: Article

References (18)

1. Oerlemans R, Franke NE, Assaraf YG, et al.: Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112: 2489-2499, 2008.
2. Smith AJ, Dai H, Correia C, et al.: Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells. J Biol Chem 286: 17682-17692, 2011.
3. Kern J, Untergasser G, Zenzmaier C, et al.: GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib. Blood 114: 3960-3967, 2009.
4. Shringarpure R, Catley L, Bhole D, et al.: Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol 134: 145-156, 2006. (Pubitemid 43893906)
5. Fournier MJ, Gareau C and Mazroui R: The chemotherapeutic agent bortezomib induces the formation of stress granules. Cancer Cell Int 10: 12, 2010.
6. Yang DT, Young KH, Kahl BS, Markovina S and Miyamoto S: Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer 7: 40, 2008.
7. Golden EB, Lam PY, Kardosh A, et al.: Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood 113: 5927-5937, 2009.
8. Hatcher H, Planalp R, Cho J, Torti FM and Torti SV: Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 65: 1631-1652, 2008.
9. Milacic V, Banerjee S, Landis-Piwowar KR, Sarkar FH, Majumdar AP and Dou QP: Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res 68: 7283-7292, 2008.
10. Bava SV, Puliappadamba VT, Deepti A, Nair A, Karunagaran D and Anto RJ: Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappaB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem 280: 6301-6308, 2005. (Pubitemid 40341176)
11. Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M and D'Alessandro N: Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-κB activation levels and in IAP gene expression. Cancer Lett 224: 53-65, 2005. (Pubitemid 40720367)
12. Chirnomas D, Taniguchi T, de la Vega M, et al.: Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 5: 952-961, 2006. (Pubitemid 43724595)
13. Park J, Ayyappan V, Bae EK, et al.: Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells. Mol Oncol 2: 317-326, 2008.
14. Sung B, Kunnumakkara AB, Sethi G, Anand P, Guha S and Aggarwal BB: Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther 8: 959-970, 2009.
15. Wan SB, Yang H, Zhou Z, et al.: Evaluation of curcumin acetates and amino acid conjugates as proteasome inhibitors. Int J Mol Med 26: 447-455, 2010.
16. Kuhn D, Lam WH, Kazi A, et al.: Synthetic peracetate tea polyphenols as potent proteasome inhibitors and apoptosis inducers in human cancer cells. Front Biosci 10: 1010-1023, 2005.
17. Chen D, Frezza M, Shakya R, et al.: Inhibition of the proteasome activity by gallium(III) complexes contributes to their anti prostate tumor effects. Cancer Res 67: 9258-9265, 2007. (Pubitemid 47535914)
18. Ma MH, Yang HH, Parker K, et al.: The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9: 1136-1144, 2003. (Pubitemid 36323723)